Paving the Way - Bristol

Paving the Way
With Innovative Research in Immuno-Oncology
Bristol-Myers Squibb is leading the way through its extensive Immuno-Oncology (I-O)
program across multiple tumor types. I-O is an innovative area of research that seeks
to help the body's own immune system to fight cancer.
Cancer is one of the leading causes
of death worldwide, accounting for
1 in 8 deaths
Estimated 2012
Worldwide Annual
Diagnosis1
Brain:
256,000+
Head & neck:
686,000+
Lung Cancer
(SCLC and NSCLC):
1.82 Million+
Melanoma:
232,000+
Breast:
1.67 Million+
Hodgkin
Lymphoma:
65,000+
Pancreatic:
337,000+
Liver:
782,000+
Bladder:
429,000+
Multiple
Myeloma:
114,000+
Non-Hodgkin
Lymphoma:
385,000+
Gastric:
951,000+
Colorectal:
1.36 Million+
Renal Cell
Carcinoma:
337,000+
The Different Types of Cancer Approaches
Traditional cancer treatment approaches are directed towards cancer cells.
ImmunoOncology
ImmunoOncology is
designed to
work with your
body's own
immune
system to help
fight cancer.
Chemotherapy
Radiation
Chemotherapy
is the use of
medicines that
kill cancer
cells.
Radiation uses
high-energy
particles or
waves to
destroy cancer
cells.
Targeted
therapy
Surgery
Surgery is an
invasive procedure
that is used to
remove tumor
tissue in an
attempt to reduce
cancer cells or
improve
symptoms in a
patient.
Targeted
therapy uses
drugs or other
treatments to
more precisely
identify and
attack cancer
cells directly.
Immuno-Oncology is different from other cancer
treatments because it is designed to work with the
body's own immune system to fight cancer
Across
In Immuno-Oncology,
Bristol-Myers Squibb
is Exploring:
6
20+
clinical targets
tumor types
The Immune
System and
Cancer
Normally, the immune system recognizes cancer cells and initiates an anti-tumor response
to eliminate cancer. However, cancer cells may evade the body’s protective immune
response by exploiting key immune checkpoint pathways that are regulators of T-cell
activity and can be used by the tumor as defense mechanisms against the immune system.
Inactive Natural Killer Cell
Activated T Cell
Activated T Cell
Activated Natural
Killer Cell
PD-1
T cell
receptor MHC
LAG-3
Tumor Cell
PD-L1 or
PD-L2
LAG-3
Tumor Cell
Cancer Cell
Adaptor
protein
CD137
PD-1
SLAMF7
SLAMF7
CD137L
KIR
Tumor Cell
CTLA-4
CD-137
Activated T Cell
CD-80
or CD86
Inactive T Cell
Antigen-Presenting Cell
CTLA-4
Antigen-Presenting Cell
Bristol-Myers Squibb is exploring the potential of a number
of immune system pathways:
as well as additional Immuno-Oncology pathways that work with
the innate immune system and tumor microenvironment
For more information, please visit ImmunoOncologyNow.com
© 2015 Bristol-Myers Squibb Company
ONCUS15UB00393-01-01 05/15